<p>/PRNewswire/ -- Belief BioMed（&#34;BBM&#34;）与大生命科学集团有限公司（&#34;Grand Life Sciences&#34;）今天宣布达成独家合作协议。根据协议，Belief BioMed 将授予 Grand Life Sciences 在中国大陆、香港、澳门和台湾的商业化其研究产品 BBM-H803 的权利。这一合作强调了双方在各自领域利用各自优势和资源的共同承诺，以加速产品的商业化进程，帮助 A 型血友病患者获得创新治疗选择，并共同推动基因治疗行业的发展。该协议由 Belief BioMed 的联合创始人、董事长兼首席科学官肖肖和大生命科学的董事长冯增辉签署。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Belief BioMed 与大生命科学的独家商业合作签约仪式</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>肖肖博士，Belief BioMed 联合创始人、董事长兼首席科学官</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>冯增辉先生，大生命科学董事长</p>
<p>Belief BioMed 的联合创始人、董事长兼首席科学官肖肖博士表示：&#34;Belief BioMed 专注于前沿的基因治疗领域，我们的产品管线涵盖稀有病和常见病，努力填补大量未满足的临床需求。2025 年，我们成功推出了中国首个用于 B 型血友病的基因治疗 BBM-H901，为该领域的患者提供了一种新颖的治疗选择。现在，转向 A 型血友病的治疗，我们很高兴与大生命科学建立这一战略合作伙伴关系。通过将 Belief BioMed 扎实的临床开发专业知识与大生命科学强大的商业化能力相结合，我们正在创造强大的协同效应，共同推进 A 型血友病基因治疗的商业化。我们期待将这一新治疗选择带给中国的 A 型血友病患者。&#34;</p>
<p>大生命科学集团董事长冯增辉先生表示：&#34;利用其子公司 Grand Shuyang 的广泛血液产品资源和在血液学领域的深厚专业知识，与 Belief BioMed 在 A 型血友病的合作代表了我们建立创新管线的关键战略举措。我们期待将 Belief BioMed 的前沿研发能力与大生命科学成熟的商业化平台和市场渠道整合在一起。我们共同的目标是高效加速患者获得这一创新疗法的机会。我们的共同目标是使更多的 A 型血友病患者能够更早受益，减轻他们频繁注射的身体负担和对出血事件的恐惧。&#34;</p>
<p><strong>关于 A 型血友病</strong></p>
<p>A 型血友病是一种由第Ⅷ因子缺乏引起的遗传性疾病，其特征是在关节、肌肉和软组织内反复发生自发性出血。反复的关节出血可能导致关节畸形，严重时会导致残疾。在中国，血友病的患病率在每 10 万人中为 2.73 至 3.09 之间。目前登记的 A 型血友病病例超过 30,000 例。目前，大多数患者依赖第Ⅷ因子作为替代治疗，尽管存在感染风险以及给药不便等问题。此外，A 型血友病患者面临多重挑战，包括治疗选择有限和缺乏标准化的诊断和治疗程序。因此，这些患者迫切需要更好的医疗护理。[3]</p>
<p><strong>关于 BBM-H803</strong></p>
<p>BBM-H803 是一种由 Belief BioMed 拥有独立知识产权的基于 AAV 的基因治疗。它通过静脉注射将凝血因子Ⅷ基因输送到 A 型血友病患者的体内，从而改善和维持患者体内的凝血因子水平，以预防出血。BBM-H803 使用肝脏靶向的衣壳和高效的基因表达盒，药物生产采用公司自主开发的无血清悬浮培养工艺，符合药品良好生产规范的要求。</p>
<p>自 2022 年以来，BBM-H803 的研究者发起试验（IIT，NCT05454774）正在进行中，并于同年 12 月获得美国 FDA 的孤儿药资格（ODD）。2023 年 7 月，BBM-H803 的临床试验申请（IND）获得中国 NMPA 批准。2024 年 10 月，该药物获得美国 FDA 的罕见儿童疾病资格（RPDD）。</p>
<p>在深厚的相互信任和无缝合作的推动下，这一合作伙伴关系将加速 Belief BioMed 在中国的 A 型血友病基因治疗的商业化。它承诺为患者带来新的希望，同时推动中国基因治疗行业的持续增长。</p>
<p><strong>参考</strong></p>
<p>[1] https://www.beliefbiomed.com/newsd-825.html</p>
<p>[2] Feng Xue 等，《中国血友病诊断与治疗报告（2024 版）》，LabMedDiscovery1(2024) 100007，https://doi.org/10.1016/j.lmd.2024.100007</p>
<p>[3] https://www.beliefbiomed.com/newsd-745.html</p>
<p><strong>关于 Belief BioMed</strong></p>
<p>Belief BioMed Inc. (BBM) 是一家全球生物科技公司，整合了基因治疗产品的研发、制造和临床应用。该公司致力于通过安全高效的病毒载体技术，为严重的遗传和慢性疾病提供创新且更有效的基因治疗。BBM 已开发出数百种关键载体技术，包括 HEK293 细胞悬浮无血清培养工艺和全规模色谱纯化工艺，并建立了基因治疗药物的商业生产平台。该公司在多个领域不断提升其能力，包括针对不同组织的新型 AAV 外壳、高效的转基因表达盒设计以及先进的临床适用载体制造工艺。它还建立了一个广泛的研发管线，涵盖了不同治疗领域中广泛未满足的临床需求，如血友病、DMD、帕金森病、骨关节炎等。多个产品管线已进入临床研究或提交了 IND 申请。用于治疗成人血友病 B 的基因治疗的生物制品许可申请（BLA）已在中国大陆和澳门获得批准。</p>
<p>欲了解更多信息，请访问：https://www.beliefbiomed.com/。</p>
<p><strong>关于大生命科学</strong></p>
<p>大生命科学总部位于北京昌平区，是一家以创新为驱动、拥有坚实产业基础的国际制药和医疗保健企业集团。经过多年的发展，集团已建立起涵盖血液制品、益生菌、疫苗、医疗营养和围手术期护理五个领域的多元化产业布局。大生命科学紧跟全球药物发现和开发的前沿技术。在临床价值和前瞻性战略规划的指导下，公司建立了独特的产品组合和覆盖整个研发生命周期的差异化管线。大生命科学在多个领域保持行业领先地位，包括血液制品、活生物治疗产品、围手术期止血和疫苗，目前拥有 30 多个核心创新产品管线。公司在北京、成都、南京、武汉和杭州建立了五个研发中心。迄今为止，已有 30 多种产品处于临床开发中，不断为公司的创新驱动增长注入新动力。大生命科学在中国近十个城市建立了高标准的制造基地，配备先进的质量管理体系。其销售网络覆盖全国所有省市，达到数十万终端网点。血液制品在全球销售，累计出口到 20 多个国家，公司持续加快国际市场的扩展。大生命科学秉持 “全心全意为人民服务” 的使命，始终坚持 “以患者和消费者为中心、以研究为基础、以市场为导向的发展” 商业理念。公司坚信 “一剂药可以拯救两条命”，积极履行企业社会责任，致力于建设全球创新的生命科学企业。</p>
<p><strong>声明</strong></p>
<p>此信息仅用于介绍公司在该日期的新闻、事件和信息，并不旨在推广任何公司的产品和/或服务，也不应被解读为提供任何药物、医疗设备和治疗方案选择的建议或推荐。</p>
<p>有关任何公司产品、疾病和/或治疗的信息，请咨询医疗专业人士。</p>
<p>此处描述的 BBM-H803 尚未获得上市批准。</p>
<p>来源：Belief BioMed</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzIzJk5ld3NJdGVtSWQ9Q04xNjI0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMjMwMTQ4UFJfTkVXU19VU1BSX19fX19DTjE2MjQ0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzIzJk5ld3NJdGVtSWQ9Q04xNjI0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMjMwMTQ4UFJfTkVXU19VU1BSX19fX19DTjE2MjQ0"/></p>

CS精准医

华东医药

远大医药

<p>Belief BioMed 和 Grand Life Sciences 宣布达成独家合作伙伴关系，在中国、香港、澳门和台湾商业化 BBM-H803，这是一种用于治疗 A 型血友病的基因疗法。此次合作旨在利用两家公司的优势，加速商业化进程，提高患者对创新治疗的获取能力。该协议由两家公司关键高管签署，彰显了他们解决 A 型血友病患者未满足临床需求的承诺。BBM-H803 是一种基于 AAV 的基因疗法，旨在提高患者的凝血因子水平，目前正在进行临床试验并获得相关监管批准</p>

<p>, /PRNewswire/ -- Belief BioMed (&#34;BBM&#34;) and Grand Life Sciences Group Co., Ltd. (&#34;Grand Life Sciences&#34;) today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational product, BBM-H803, in Mainland China, Hong Kong China, Macau China, and Taiwan China. The collaboration underscores the shared commitment of both sides to leverage their respective strengths and resources in their respective fields, to accelerate the commercialization process of the product, help hemophilia A patients access innovative treatment option, and jointly promote the development of the gene therapy industry. The agreement was signed by Xiao Xiao, Co-founder, Chairman and CSO of Belief BioMed, and Zenghui, Feng, Chairman of Grand Life Sciences.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Belief BioMed（&#34;BBM&#34;）与大生命科学集团有限公司（&#34;Grand Life Sciences&#34;）今天宣布达成独家合作协议。根据协议，Belief BioMed 将授予 Grand Life Sciences 在中国大陆、香港、澳门和台湾的商业化其研究产品 BBM-H803 的权利。这一合作强调了双方在各自领域利用各自优势和资源的共同承诺，以加速产品的商业化进程，帮助 A 型血友病患者获得创新治疗选择，并共同推动基因治疗行业的发展。该协议由 Belief BioMed 的联合创始人、董事长兼首席科学官肖肖和大生命科学的董事长冯增辉签署。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Signing Ceremony for the Exclusive Commercial Collaboration Between Belief BioMed and Grand Life Sciences</p>
<div class="lb-trans"><p>Belief BioMed 与大生命科学的独家商业合作签约仪式</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Dr. Xiao Xiao Co-founder, Chairman and Chief Science Officer, Belief BioMed</p>
<div class="lb-trans"><p>肖肖博士，Belief BioMed 联合创始人、董事长兼首席科学官</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Mr. Zenghui Feng Chairman, Grand Life Sciences</p>
<div class="lb-trans"><p>冯增辉先生，大生命科学董事长</p>
</div><p>Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of Belief BioMed, said, &#34;Belief BioMed focuses on the cutting-edge gene therapy field, with our product pipeline covering the rare and common diseases, striving to fill a large number of unmet clinical needs. In 2025, we successfully launched China's first gene therapy for Hemophilia B, BBM-H901, providing a novel treatment option for patients in this field. Now, turning to the treatment of hemophilia A, we are delighted to forge this strategic partnership with Grand Life Sciences. By combining Belief BioMed's solid clinical development expertise with Grand Life Sciences' robust commercialization capabilities, we are creating a powerful synergy to jointly advance the commercialization of gene therapies for hemophilia A. We look forward to bringing this new treatment option to hemophilia A patients in China.&#34;</p>
<div class="lb-trans"><p>Belief BioMed 的联合创始人、董事长兼首席科学官肖肖博士表示：&#34;Belief BioMed 专注于前沿的基因治疗领域，我们的产品管线涵盖稀有病和常见病，努力填补大量未满足的临床需求。2025 年，我们成功推出了中国首个用于 B 型血友病的基因治疗 BBM-H901，为该领域的患者提供了一种新颖的治疗选择。现在，转向 A 型血友病的治疗，我们很高兴与大生命科学建立这一战略合作伙伴关系。通过将 Belief BioMed 扎实的临床开发专业知识与大生命科学强大的商业化能力相结合，我们正在创造强大的协同效应，共同推进 A 型血友病基因治疗的商业化。我们期待将这一新治疗选择带给中国的 A 型血友病患者。&#34;</p>
</div><p>Mr. Zenghui Feng, Chairman of Grand Life Sciences Group, said, &#34;Leveraging our extensive blood product resources of its subsidiary, Grand Shuyang, and deep expertise in the field of hematology, this collaboration with Belief BioMed in hemophilia A represents a pivotal strategic move to build our innovative pipeline. We look forward to integrating Belief BioMed's cutting-edge R&amp;D capabilities with Grand Life Sciences' mature commercialization platform and market channels. Together, we aim to efficiently accelerate the patient access to this innovative therapy in China. Our shared goal is to enable more hemophilia A patients to benefit earlier, relieving them from the physical burden of frequent injections and the fear of bleeding episodes.&#34;</p>
<div class="lb-trans"><p>大生命科学集团董事长冯增辉先生表示：&#34;利用其子公司 Grand Shuyang 的广泛血液产品资源和在血液学领域的深厚专业知识，与 Belief BioMed 在 A 型血友病的合作代表了我们建立创新管线的关键战略举措。我们期待将 Belief BioMed 的前沿研发能力与大生命科学成熟的商业化平台和市场渠道整合在一起。我们共同的目标是高效加速患者获得这一创新疗法的机会。我们的共同目标是使更多的 A 型血友病患者能够更早受益，减轻他们频繁注射的身体负担和对出血事件的恐惧。&#34;</p>
</div><p><strong>About Hemophilia A</strong></p>
<div class="lb-trans"><p><strong>关于 A 型血友病</strong></p>
</div><p>Hemophilia A is a genetic disorder caused by the deficiency of factor Ⅷ, and it is characterized by reoccurring, spontaneous bleeding episodes within joints, muscles, and soft tissues. Reoccurring joints bleeding can result in joint deformity, and disability in severe cases. In China, the hemophilia prevalence rate stands between 2.73 and 3.09 per 100,000 people. There are over 30,000 registered cases of hemophilia A. Currently, most patients rely on factor Ⅷ as a replacement therapy, despite the risk of exposure to infection, together with inconvenience of administration. Furthermore, patients with hemophilia A face multiple challenges, including limited treatment options and a lack of standardized diagnostic and therapeutic procedures. Consequently, there is a pressing unmet need for better medical care among these patients. [3]</p>
<div class="lb-trans"><p>A 型血友病是一种由第Ⅷ因子缺乏引起的遗传性疾病，其特征是在关节、肌肉和软组织内反复发生自发性出血。反复的关节出血可能导致关节畸形，严重时会导致残疾。在中国，血友病的患病率在每 10 万人中为 2.73 至 3.09 之间。目前登记的 A 型血友病病例超过 30,000 例。目前，大多数患者依赖第Ⅷ因子作为替代治疗，尽管存在感染风险以及给药不便等问题。此外，A 型血友病患者面临多重挑战，包括治疗选择有限和缺乏标准化的诊断和治疗程序。因此，这些患者迫切需要更好的医疗护理。[3]</p>
</div><p><strong>About BBM-H803</strong></p>
<div class="lb-trans"><p><strong>关于 BBM-H803</strong></p>
</div><p>BBM-H803 is an AAV-based gene therapy with independent intellectual property rights owned by Belief BioMed. It is administered intravenously to deliver the coagulation factor Ⅷ gene into the body of patients with hemophilia A, thereby improving and maintaining the coagulation factor level in the patient's body for a long time, for the prevention of bleeding. BBM-H803 uses liver-tropic capsid and highly efficient gene expression cassette, and the drug production uses the company's independently developed serum-free suspension culture process, which meets the requirements of the Good Manufacturing Practice for Pharmaceuticals.</p>
<div class="lb-trans"><p>BBM-H803 是一种由 Belief BioMed 拥有独立知识产权的基于 AAV 的基因治疗。它通过静脉注射将凝血因子Ⅷ基因输送到 A 型血友病患者的体内，从而改善和维持患者体内的凝血因子水平，以预防出血。BBM-H803 使用肝脏靶向的衣壳和高效的基因表达盒，药物生产采用公司自主开发的无血清悬浮培养工艺，符合药品良好生产规范的要求。</p>
</div><p>Since 2022, the Investigator Initiated Trial (IIT, NCT05454774) of BBM-H803 has been on-going, and in December of the same year, BBM-H803 was granted Orphan Drug Designation (ODD) by the U.S. FDA. In July 2023, the Investigational New Drug (IND) application for BBM-H803 was approved by China NMPA. In October 2024, the drug received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA.</p>
<div class="lb-trans"><p>自 2022 年以来，BBM-H803 的研究者发起试验（IIT，NCT05454774）正在进行中，并于同年 12 月获得美国 FDA 的孤儿药资格（ODD）。2023 年 7 月，BBM-H803 的临床试验申请（IND）获得中国 NMPA 批准。2024 年 10 月，该药物获得美国 FDA 的罕见儿童疾病资格（RPDD）。</p>
</div><p>Driven by deep mutual trust and seamless collaboration, this partnership will accelerate the commercialization of Belief BioMed's hemophilia A gene therapies in China. It promises to bring new hope to patients while fueling the continued growth of China's gene therapy sector.</p>
<div class="lb-trans"><p>在深厚的相互信任和无缝合作的推动下，这一合作伙伴关系将加速 Belief BioMed 在中国的 A 型血友病基因治疗的商业化。它承诺为患者带来新的希望，同时推动中国基因治疗行业的持续增长。</p>
</div><p><strong>Reference</strong></p>
<div class="lb-trans"><p><strong>参考</strong></p>
</div><p>[1] https://www.beliefbiomed.com/newsd-825.html</p>
<div class="lb-trans"><p>[1] https://www.beliefbiomed.com/newsd-825.html</p>
</div><p>[2] Feng Xue, et al，Report on the diagnosis and treatment of hemophilia in China (Version 2024)，LabMedDiscovery1(2024) 100007, https://doi.org/10.1016/j.lmd.2024.100007</p>
<div class="lb-trans"><p>[2] Feng Xue 等，《中国血友病诊断与治疗报告（2024 版）》，LabMedDiscovery1(2024) 100007，https://doi.org/10.1016/j.lmd.2024.100007</p>
</div><p>[3] https://www.beliefbiomed.com/newsd-745.html</p>
<div class="lb-trans"><p>[3] https://www.beliefbiomed.com/newsd-745.html</p>
</div><p><strong>About Belief BioMed</strong></p>
<div class="lb-trans"><p><strong>关于 Belief BioMed</strong></p>
</div><p>Belief BioMed Inc. (BBM) is a global biotech company that integrates the research and development, manufacturing and clinical application of gene therapy products. The company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology. BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production platform for gene therapy drugs. The company has been building up its capabilities in a variety of fields including novel AAV capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinically applicable vector manufacturing process. It has also established an extensive R&amp;D pipeline covering a wide range of unmet clinical needs in different therapeutic areas such as hemophilia, DMD, Parkinson's disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted IND filings. The Biologics License Application (BLA) of a gene therapy for the treatment of adult patients with hemophilia B, has been approved in Mainland China and Macao China.</p>
<div class="lb-trans"><p>Belief BioMed Inc. (BBM) 是一家全球生物科技公司，整合了基因治疗产品的研发、制造和临床应用。该公司致力于通过安全高效的病毒载体技术，为严重的遗传和慢性疾病提供创新且更有效的基因治疗。BBM 已开发出数百种关键载体技术，包括 HEK293 细胞悬浮无血清培养工艺和全规模色谱纯化工艺，并建立了基因治疗药物的商业生产平台。该公司在多个领域不断提升其能力，包括针对不同组织的新型 AAV 外壳、高效的转基因表达盒设计以及先进的临床适用载体制造工艺。它还建立了一个广泛的研发管线，涵盖了不同治疗领域中广泛未满足的临床需求，如血友病、DMD、帕金森病、骨关节炎等。多个产品管线已进入临床研究或提交了 IND 申请。用于治疗成人血友病 B 的基因治疗的生物制品许可申请（BLA）已在中国大陆和澳门获得批准。</p>
</div><p>For more information, please visit: https://www.beliefbiomed.com/.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.beliefbiomed.com/。</p>
</div><p><strong>About Grand Life Sciences</strong></p>
<div class="lb-trans"><p><strong>关于大生命科学</strong></p>
</div><p>Headquartered in Changping District, Beijing, Grand Life Sciences is an international pharmaceutical and healthcare enterprise group driven by innovation and supported by a solid industrial foundation. After years of development, the Group has built a diversified industrial layout covering five sectors: blood products, probiotics, vaccines, medical nutrition, and perioperative care. Grand Life Sciences closely tracks cutting-edge technologies in global drug discovery and development. Guided by clinical value and forward-looking strategic planning, the company has built a distinctive product portfolio and a differentiated pipeline covering the entire R&amp;D lifecycle. Grand Life Sciences maintains industry-leading positions across multiple fields, including blood products, live biotherapeutic products, perioperative hemostasis, and vaccines, and currently has more than 30 core innovative product pipelines. The company has established five R&amp;D centers in Beijing, Chengdu, Nanjing, Wuhan, and Hangzhou. To date, more than 30 products are in clinical development, continuously injecting new momentum into the company's innovation-driven growth. Grand Life Sciences has built high-standard manufacturing bases with advanced quality management systems in nearly ten cities across China. Its sales network covers all provinces and municipalities nationwide, reaching hundreds of thousands of terminal outlets. Blood products are sold globally, with cumulative exports to more than 20 countries, and the company continues to accelerate its expansion into international markets.With the mission of &#34;serving the people wholeheartedly,&#34; Grand Life Sciences consistently upholds the business philosophy of &#34;patient- and consumer-centered, research-based, and market-oriented development.&#34; Guided by the belief that &#34;one dose of medicine can save two lives,&#34; the company actively fulfills its corporate social responsibilities and is committed to building a globally innovative enterprise in the life sciences sector.</p>
<div class="lb-trans"><p>大生命科学总部位于北京昌平区，是一家以创新为驱动、拥有坚实产业基础的国际制药和医疗保健企业集团。经过多年的发展，集团已建立起涵盖血液制品、益生菌、疫苗、医疗营养和围手术期护理五个领域的多元化产业布局。大生命科学紧跟全球药物发现和开发的前沿技术。在临床价值和前瞻性战略规划的指导下，公司建立了独特的产品组合和覆盖整个研发生命周期的差异化管线。大生命科学在多个领域保持行业领先地位，包括血液制品、活生物治疗产品、围手术期止血和疫苗，目前拥有 30 多个核心创新产品管线。公司在北京、成都、南京、武汉和杭州建立了五个研发中心。迄今为止，已有 30 多种产品处于临床开发中，不断为公司的创新驱动增长注入新动力。大生命科学在中国近十个城市建立了高标准的制造基地，配备先进的质量管理体系。其销售网络覆盖全国所有省市，达到数十万终端网点。血液制品在全球销售，累计出口到 20 多个国家，公司持续加快国际市场的扩展。大生命科学秉持 “全心全意为人民服务” 的使命，始终坚持 “以患者和消费者为中心、以研究为基础、以市场为导向的发展” 商业理念。公司坚信 “一剂药可以拯救两条命”，积极履行企业社会责任，致力于建设全球创新的生命科学企业。</p>
</div><p><strong>Statement</strong></p>
<div class="lb-trans"><p><strong>声明</strong></p>
</div><p>This information is only for the purpose of introducing the company's news, events and information on that date, and is not intended to promote any company's products and/or services, nor should it be construed as providing any advice or recommendation on the selection of any drugs, medical devices and treatment options.</p>
<div class="lb-trans"><p>此信息仅用于介绍公司在该日期的新闻、事件和信息，并不旨在推广任何公司的产品和/或服务，也不应被解读为提供任何药物、医疗设备和治疗方案选择的建议或推荐。</p>
</div><p>For information about any company products, diseases and/or treatments, please consult a healthcare professional.</p>
<div class="lb-trans"><p>有关任何公司产品、疾病和/或治疗的信息，请咨询医疗专业人士。</p>
</div><p>BBM-H803 described herein has not been approved for marketing.</p>
<div class="lb-trans"><p>此处描述的 BBM-H803 尚未获得上市批准。</p>
</div><p>SOURCE Belief BioMed</p>
<div class="lb-trans"><p>来源：Belief BioMed</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzIzJk5ld3NJdGVtSWQ9Q04xNjI0NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMjMwMTQ4UFJfTkVXU19VU1BSX19fX19DTjE2MjQ0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN16244&amp;Transmission_Id=202603230148PR_NEWS_USPR_____CN16244&amp;DateId=20260323"/></p>

01:48 ETBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

prnewswire

华夏上证科创板生物医药ETF

博时恒生港股通创新药精选ETF

招商中证生物科技主题ETF

国泰上证科创板创新药ETF

汇添富国证港股通创新药ETF

华夏恒生生物科技ETF(QDII)

国泰中证生物医药ETF

华夏医药ETF

博时恒生医疗保健(QDII-ETF)

华泰柏瑞恒生创新药ETF(QDII)

富国恒生港股通创新药及医疗保健ETF

易方达恒生港股通创新药ETF

华宝中证制药ETF

易方达沪深300医药ETF

创新药

广发中证香港创新药(QDII-ETF)

生物科技ETF基金

华夏中证生物科技主题ETF

汇添富中证医药卫生ETF

易方达中证生物科技主题ETF

华宝恒生港股通创新药精选ETF

香港医药

01:48 ET Belief BioMed 和 Grand Life Sciences 宣布在 A 型血友病领域达成独家商业合作，旨在为中国患者引入创新的基因疗法